
|Articles|October 1, 1996
The American Journal of Managed Care
- October 1996
- Volume 2
- Issue 9
Use of a New Antiepileptic Drug in an HMO: Economic Outcomes from the Payer Perspective
Advertisement
Articles in this issue
about 29 years ago
The Influence of New Devices on the Costs of Interventional Proceduresabout 29 years ago
Patterns of Antidepressant Use and Their Relation to Costs of Careabout 29 years ago
The Psychopharmacology of Depression in the Managed Care Settingabout 29 years ago
Cost-Effective Treatment of DepressionNewsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
CAR T-Cell Therapies, Bispecific Antibodies Usher in New Era in R/R MCL
2
Emerging Breakthroughs in Neurodegenerative Disease Treatments: Kavita Nair, PhD, FAAN
3
Ibrutinib-Based Frontline Regimens Narrow the Survival Gap in CLL
4
Missed Hepatitis B Treatment Opportunities in the US Increase Health Risks
5















































